Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)

NCT07286747 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

390

Enrollment

OTHER

Sponsor class

Conditions

Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)

Interventions

DRUG: controlled-ileal-release nicotinic acid as multiple dose 100 mg/day
DRUG: controlled-ileal-release nicotinic acid as multiple dose 200 mg/day
DRUG: controlled-ileal-release nicotinic acid as multiple dose placebo

Sponsor

University Hospital Schleswig-Holstein